@article{5c082db65793474188d2c2c0ca4214fe,
title = "Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology",
abstract = "There is an unmet need for effective treatment strategies to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in patients with HFpEF was almost exclusively focused on the left side. However, it is now increasingly recognized that right heart dysfunction is common and contributes importantly to poor prognosis in HFpEF. More insights into the development of right heart dysfunction in HFpEF may aid to our knowledge about this complex disease and may eventually lead to better treatments to improve outcomes in these patients. In this position paper from the Heart Failure Association of the European Society of Cardiology, the Committee on Heart Failure with Preserved Ejection Fraction reviews the prevalence, diagnosis, and pathophysiology of right heart dysfunction and failure in patients with HFpEF. Finally, potential treatment strategies, important knowledge gaps and future directions regarding the right side in HFpEF are discussed.",
keywords = "Biomarkers, Heart failure, Heart failure with preserved ejection fraction, Pulmonary hypertension, Right ventricular function",
author = "Gorter, {Thomas M.} and {van Veldhuisen}, {Dirk J.} and Johann Bauersachs and Borlaug, {Barry A.} and Jelena Celutkiene and Coats, {Andrew J.S.} and Crespo-Leiro, {Marisa G.} and Marco Guazzi and Harjola, {Veli Pekka} and Stephane Heymans and Loreena Hill and Mitja Lainscak and Lam, {Carolyn S.P.} and Lund, {Lars H.} and Lyon, {Alexander R.} and Alexandre Mebazaa and Christian Mueller and Paulus, {Walter J.} and Burkert Pieske and Piepoli, {Massimo F.} and Frank Ruschitzka and Rutten, {Frans H.} and Seferovic, {Petar M.} and Solomon, {Scott D.} and Shah, {Sanjiv J.} and Filippos Triposkiadis and Rolf Wachter and Carsten Tsch{\"o}pe and {de Boer}, {Rudolf A.}",
note = "Funding Information: The authors thank Gerasimos S. Filippatos (National and Kapodis-trian University of Athens, School of Medicine, Athens University Hospital Attikon, Athens, Greece) for support and useful suggestions. Dr. de Boer is supported by the Netherlands Heart Foundation (CVON-DOSIS, grant 2014-40) and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). Conflict of interest: T.M.G. reports no conflict of interest; D.J.v.V. reports no conflict of interest; J.B. reports grants from Bayer and MSD, outside the submitted work; B.A.B. reports support from Aires Pharmaceuticals, Inc., GlaxoSmithKline and Medtronic, and personal fees from Amgen and Merck & Co, Inc., outside the submitted work; J.C. reports grants from Lithuanian Research Council, non-financial support from Medispec, and personal fees from Novartis, Servier, Orivas, Amgen, and Grindex, outside the submitted work; A.J.S.C. reports no conflict of interest; M.G.C-L. reports no conflict of interest; M.G. reports no conflict of interest; V-P.H. reports personal fees from Orion Pharma, outside the submitted work; S.H. reports no conflict of interest; L.H. reports no conflict of interest; M.L. reports no conflict of interest; C.S.P.L. reports grants from National Medical Research Council of Singapore, non-financial support from Boston Scientific, Bayer, Thermofisher, Medtronic, Vifor Pharma, personal fees from Bayer, Novartis, Takeda, Merck, Astra Zeneca, Janssen Research & Development, LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, Roche and Amgen, and dr. Lam has a patent PCT/SG2016/050217 pending, outside the submitted work; L.H.L. reports consultancy fees from Bayer, AstraZeneca, ViforPharma, Novartis, Sanofi, Fresenius and Relypsa, institutional grants from ViforPharma, Boehringer Ingel-heim and Boston Scientific, speaker fees and/or travel expenses from Novartis, AstraZeneca and St Jude, outside the submitted work; A.R.L. reports no conflict of interest; A.M. reports personal fees from Novartis, Orion, Roche, Servier, Zs Pharma and Cardiorentis, grants and personal fees from Adrenomed, grants from MyCartis, Critical Diagnostics, outside the submitted work; C.M. reports grants, personal fees and non-financial support from Several diagnostic companies, outside the submitted work; W.J.P. reports no conflict of interest; B.P. reports no conflict of interest; M.F.P. reports no conflict of interest; F.R. reports grants and/or personal fees from St Jude Medical, Servier, Zoll, AstraZeneca, Sanofi, Cardiorentis, Novartis, Amgen, BMS, Pfizer, Publisher Copyright: {\textcopyright} 2017 The Authors. European Journal of Heart Failure {\textcopyright} 2017 European Society of Cardiology",
year = "2018",
month = jan,
doi = "10.1002/ejhf.1029",
language = "English (US)",
volume = "20",
pages = "16--37",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "1",
}